Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia

被引：0
|
作者：
Hiroyuki Hashimoto
Masato Takeuchi
Koji Kawakami
机构：
[1] Kyoto University,Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health
来源：
Clinical Rheumatology | 2023年 / 42卷
关键词：
Allopurinol; Cardiovascular risk; Epidemiology; Febuxostat; Gout; Hyperuricemia; Xanthine oxidase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3075 / 3082
页数：7
相关论文
共 50 条
  • [21] Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database
    Masataka Honda
    Hideki Horiuchi
    Tomoko Torii
    Akihiro Nakajima
    Takeshi Iijima
    Hiroshi Murano
    Hisashi Yamanaka
    Shuichi Ito
    BMC Pediatrics, 21
  • [22] The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
    Michael A Becker
    H Ralph Schumacher
    Luis R Espinoza
    Alvin F Wells
    Patricia MacDonald
    Eric Lloyd
    Christopher Lademacher
    Arthritis Research & Therapy, 12 (2):
  • [23] What is the Best Choice for Urate-lowering Therapy for Korean?
    Cheon, Yun-Hong
    Song, Jung Soo
    JOURNAL OF RHEUMATIC DISEASES, 2020, 27 (02): : 78 - 87
  • [24] The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5
    Liu, Xuemei
    Wang, Huifang
    Ma, Ruixia
    Shao, Leping
    Zhang, Wei
    Jiang, Wei
    Luo, Congjuan
    Zhai, Tingting
    Xu, Yan
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2019, 23 (03) : 362 - 370
  • [25] Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia
    Chen, Mo
    Ye, Chenyi
    Zhu, Jianing
    Zhang, Peiyu
    Jiang, Yujie
    Lu, Xiaoyong
    Wu, Huaxiang
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [26] Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review
    Beslon, Virginie
    Moreau, Perrine
    Maruani, Annabel
    Maisonneuve, Hubert
    Giraudeau, Bruno
    Fournier, Jean-Pascal
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 (03) : 358 - 366
  • [27] Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout
    Graham, Garry G.
    Stocker, Sophie L.
    Kannangara, Diluk R. W.
    Day, Richard O.
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (08)
  • [28] Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout
    Lisa K. Stamp
    Peter T. Chapman
    Drugs & Aging, 2014, 31 : 777 - 786
  • [29] Potential Dangers of Serum Urate-Lowering Therapy
    Vanessa Perez-Gomez, Maria
    Bartsch, Lorenz-Alexander
    Castillo-Rodriguez, Esmeralda
    Fernandez-Prado, Raul
    Kanbay, Mehmet
    Ortiz, Alberto
    AMERICAN JOURNAL OF MEDICINE, 2019, 132 (04) : 457 - 467
  • [30] The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3–5
    Xuemei Liu
    Huifang Wang
    Ruixia Ma
    Leping Shao
    Wei Zhang
    Wei Jiang
    Congjuan Luo
    Tingting Zhai
    Yan Xu
    Clinical and Experimental Nephrology, 2019, 23 : 362 - 370
12345